KAD-1229 + Placebo + Insulin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
84
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
โ โ โ
NCT ID
NCT02154347About KAD-1229 + Placebo + Insulin
KAD-1229 + Placebo + Insulin is a approved stage product being developed by Kissei Pharmaceutical for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02154347. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02154347 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus